Apyx Medical (NASDAQ:APYX) Bolsa

Apyx Medical

Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.

Bovie Medical

Apyx Medical Corp

WIIM

Western Digital shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results and issued Q4 adjusted EPS guidance above estimates. Additionally, the company declared a quarterly dividend of $0.10 per share.

News

NBIS

DDN Partners With Nebius To Deliver Seamless Performance For Enterprise AI Workloads

CLRB

CLRB stock has given up its prior gain. Cellectar Biosciences shares were trading higher after the company announced a plan to explore strategic alternatives.

<ul>
<li>Final marketing authorization decision for early-stage breast cancer is expected upon the FDA's approval of&nbsp;IceCure's post-market study plan</li>
<li>IceCure to engage with potential clinical sites, breast surgeons and radiologists for the post-market study including at the upcoming American Society of Breast Surgeons (ASBrS) Annual Meeting</li>
<li>ProSense&#xAE; would become the first-in-class minimally invasive choice—a major advancement in women's health and a new paradigm in breast cancer care as a simple out-patient procedure</li>
<li>U.S. sales and distribution team ready to drive sales of&nbsp;ProSense&#xAE; systems and disposable probes—supporting medical community and patients looking for a new minimally invasive option to lumpectomy</li>
</ul>
<a href="https://icecure-medical.com/">IceCure Medical Ltd.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it concluded a productive meeting with the leadership of the U.S. Food and Drug Administration's ("FDA") Center for Devices and Radiological Health ("CDRH") regarding the Company's De Novo marketing authorization request for ProSense&#xAE; in the treatment of early-stage low risk breast cancer when combined with adjuvant endocrine therapy for women aged 70 and over which represents approximately 46,000 patients annually in the U.S.
During the meeting, the FDA requested that IceCure conduct a study after marketing authorization has been granted ("the post-market study"), with the aim of producing additional data in this indication. IceCure will present its post-market study plan, which is expected to include a minimum of 400 patients at 25 sites, to the FDA, and upon the CDRH's approval of such plan, the FDA's final marketing authorization decision is expected.
IceCure is now working diligently on the plan of the post-market study which IceCure plans to submit in approximately a few weeks. The Company is in the process of recruiting clinical sites and doctors across the U.S., including at the American Society of Breast Surgeons (ASBrS) Annual Meeting which takes place April 30 – May 4, 2025. The Company believes this post-market study will support accelerated market adoption of ProSense&#xAE; in early-stage breast cancer.
"This is a very positive development, and we are pleased to have had such a positive discussion with the FDA's CDRH leadership so that women aged 70 and over across America can have access to a minimally invasive option for early-stage breast cancer with ProSense&#xAE;," stated Eyal Shamir, IceCure's Chief Executive Officer. "We are laser focused on the plan of our post-market study and look forward to finalizing it following deep engagement with the leading breast surgeons and radiologists in the U.S., including at ASBrS this week. As such, the meeting with the FDA is very well timed. We look forward to the FDA's approval of our post-market study plan and final marketing authorization decision for ProSense&#xAE; in this indication. Our U.S. sales team is ready for commercialization."

Biotech

General

ICCM

IceCure Medical  Announces Meeting With Leadership Of The U.S. Food And Drug Administration's Center For Devices And Radiological Health Regarding The Company's De Novo Marketing Authorization Request For Prosense In The Treatment of Early-Stage Low Risk Breast Cancer When Combined With Adjuvant Endocrine Therapy For Women Aged 70

Benchmark analyst Cody Acree upgrades Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) from Hold to Buy and announces $95 price target.

Upgrades

Price Target

Analyst Ratings

QRVO

Benchmark Upgrades Qorvo to Buy, Announces $95 Price Target

D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) with a Buy and maintains $17 price target.

IMUX

D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target

Svenska Handelsbanken (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SVNLY#OTC">SVNLY</a>) reported quarterly earnings of $0.15 per share which missed the analyst consensus estimate of $2.97 by 94.95 percent. This is a 6.25 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $1.38 billion which missed the analyst consensus estimate of $14.60 billion by 90.52 percent. This is a 6.11 percent decrease over sales of $1.47 billion the same period last year.

Earnings

Earnings Misses

SVNLY

Svenska Handelsbanken Q1 EPS $0.15 Misses $2.97 Estimate, Sales $1.38B Miss $14.60B Estimate

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/29/final-trades-netflix-abbvie-ishares-u-s-industrials-etf-and-sherwin-williams.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management named Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) as <a href="https://in.benzinga.com/news/25/04/44955413/netflix-stock-rallies-on-last-weeks-earnings-beat-tariff-resilience-as-markets-climb-on-trade-optimism">his final trade</a>.
On the earnings front, Netflix reported first-quarter revenue of $10.54 billion on April 17, up 12.5% year-over-year. The revenue total beat a Street consensus estimate of $10.52 billion, according to data from Benzinga Pro. The company reported earnings per share of $6.61, beating a Street consensus estimate of $5.74.
Jason Snipe of Odyssey Capital Advisors said AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported robust earnings.
The company reported an adjusted EPS of $2.46 on Friday, up 6.5% year over year, beating the consensus of $2.38. The pharmaceutical giant reported sales of $13.34 billion, up 8.4% on a reported basis (+9.8% on an operational basis), beating the consensus of $12.92 billion.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Shannon Saccocia of NB Private Wealth picked iShares U.S. Industrials ETF (CBOE: IYJ) as her final trade, saying there is some insulation for aerospace and defense from tariffs.
Stephanie Link of Hightower Advisors said The Sherwin-Williams Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) reported a great quarter.
On Tuesday, Sherwin-Williams posted first-quarter adjusted earnings of $2.25 per share, beating market expectations of $2.16 per share.
Price Action:
<ul>
<li>Netflix shares gained 1.4% to close at $1,125.64 on Tuesday.</li>
<li>AbbVie gained 0.6% to close at $193.51 during Tuesday's session.</li>
<li>iShares U.S. Industrials ETF gained 0.8% on Tuesday.</li>
<li>Sherwin-Williams shares climbed 4.8% to settle at $348.13 during the session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

Media

Trading Ideas

ABBV

iShares Trust Dow Jones US Industrial Sector Index Fund

NFLX

Netflix, Sherwin-Williams, AbbVie And More On CNBC's 'Final Trades'

Lantheus Holdings, Inc.&nbsp;("Lantheus") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that its clinical-stage F18-labeled tau Positron Emission Tomography (PET) radiodiagnostic, MK-6240 (F18-florquinitau), successfully met its co-primary endpoints in two pivotal studies assessing its sensitivity and specificity. This achievement reinforces the potential of MK-6240 as a valuable diagnostic tool. The data from these two studies will support a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) expected to be filed in the third quarter of 2025.

LNTH

Lantheus Holdings' Clinical-Stage F18-labeled tau PET Radiodiagnostic, MK-6240, Meets Co-primary Endpoints In Two Pivotal Studies Assessing Sensitivity And Specificity

LANC

Lancaster Colony shares are trading lower after the company reported worse-than-expected Q3 financial results.

Contracts

QUBT

Quantum Computing Wins $406K Contract To Support NASA's Space Based LIDAR Data Analysis

OSS to deliver 80 best-in-class high performance servers and&nbsp;field-programmable gate array systems designed for a mobile intelligence platform
Record $6.5 million contract reflects the Company's multi-year growth strategy&nbsp;that is focused on establishing production platform positions
ESCONDIDO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (OSS or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSS#NASDAQ">OSS</a>), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) and sensor processing at the edge, today announced a $6.5 million contract from a leading defense and technology solutions company. OSS expects shipments to commence in 2025 and contribute to revenue throughout the year.
Under the terms of the contract, OSS will deliver 80 high performance servers and field-programmable gate array (FPGA) systems engineered for mobile, tactical military environments. The platform will be built around the Company's 3U SDS rugged servers and 4UP PCIe expansion systems. OSS' equipment is a key element in a U.S. Department of Defense program that is collecting sensor information, providing users with AI generated real-time analysis, and storing the collected data, all in a tactical environment.
The contract is the third program win over the past eight months with this customer, embedding the Company's Enterprise Class compute and storage products deeper into next-generation U.S. Department of Defense initiatives.

One Stop Systems Receives $6.5M Contract From A Leading Defense And Technology Solutions Company For 80 High Performance Servers And Field-Programmable Gate Array Systems Engineered For Mobile, Tactical Military Environments

Evercore ISI Group analyst Jonathan Chappell downgrades Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) from In-Line to Underperform and lowers the price target from $27 to $21.

Downgrades

WERN

Evercore ISI Group Downgrades Werner Enterprises to Underperform, Lowers Price Target to $21

Evercore shares are trading higher after the company reported better-than-expected Q1 financial results.

Herc Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>) ("Herc" or "the Company") announced today that it has extended its previously announced tender offer (the "Offer") to acquire all of the outstanding shares of H&amp;E Equipment Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEES#NASDAQ">HEES</a>) ("H&amp;E") common stock for $78.75 in cash and 0.1287 shares of Herc common stock for each H&amp;E share, in each case without interest, pursuant to the terms of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.hercrentals.com%2Fnews%2Fnews-details%2F2025%2FHerc-Holdings-and-HE-Equipment-Services-Enter-into-Definitive-Merger-Agreement%2Fdefault.aspx&amp;esheet=54246350&amp;newsitemid=20250430547514&amp;lan=en-US&amp;anchor=previously+announced+merger+agreement&amp;index=1&amp;md5=d6bb3cf2431140b97610c3f30c8f9e34">previously announced merger agreement</a>, dated February 19, 2025, between Herc, HR Merger Sub, Inc. and H&amp;E (the "Merger Agreement").
The Offer, which was previously scheduled to expire at one minute past 11:59 p.m. Eastern Time, on April 29, 2025, has been extended until one minute past 11:59 p.m. Eastern Time, on May 13, 2025, unless further extended in accordance with the terms of the Merger Agreement. The Offer was extended to allow additional time for the satisfaction of the remaining conditions of the tender offer, including receipt of applicable regulatory approvals. The Offer remains subject to the conditions to the completion of the Offer, as set forth in the Prospectus/Offer to Exchange, dated March 19, 2025 (as subsequently amended), the related Letter of Transmittal and certain other Offer documents, copies of which are attached to the Tender Offer Statement on Schedule TO filed by the Company and H&amp;E with the U.S. Securities and Exchange Commission (the "SEC") on March 19, 2025 (as subsequently amended).

HEES

Herc Holdings Extends Its Previously Announced Tender Offer To Acquire All Of The Outstanding Shares of H&E Equipment Services Common Stock For $78.75 In Cash And 0.1287 Shares Of Herc Common Stock for Each H&E Share

VICR

Vicor shares are trading lower after the company reported Q1 financial results and missed its EPS and sales estimates.

SIDU

Sidus Space Signs MoU With Saturn Satellite Networks To Support Development Of Next-generation GEO Satellite Platform

Jones Trading analyst Jason Weaver maintains Seven Hills Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEVN#NASDAQ">SEVN</a>) with a Buy and maintains $15 price target.

SEVN

Jones Trading Maintains Buy on Seven Hills Realty Trust, Maintains $15 Price Target

Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) and Mastercard Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) may be the titans of payments, but <a href="https://www.benzinga.com/topic/payments">their trajectories diverge sharply</a>.
Which one should investors put their chips on?
<h2 class="wp-block-heading">Visa: A Steady Hand Amid Volatility</h2>
Visa's second-quarter results came in with little drama; investors are here for it. While some expected a slowdown, Visa delivered with solid numbers, beating both revenue and EPS estimates. Cross-border volumes were up 13%, and domestic volumes were up 5.9%. Even with a slight deceleration in growth, the results indicate the model's resilience.
JPMorgan analyst Tien-tsin Huang isn't surprised, reaffirming his "Overweight" rating with a price target of $375 by the end of 2025. 
For stock investors, Visa's stable performance and robust global reach make it the &#8216;safe bet&#8217; in uncertain markets, especially with its strong pricing power and diversified model. It's the kind of stock that makes you feel secure &#8211; like a well-diversified portfolio in a rising market.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/04/45083885/visa-shares-move-higher-after-better-than-expected-q2-results-details">Visa Shares Move Higher After Better-Than-Expected Q2 Results: Details</a>
<h2 class="wp-block-heading">Mastercard: The Risk-Taker's Play</h2>
Mastercard, on the other hand, isn't quite as smooth. With its first quarter earnings due Thursday, analysts are cautiously optimistic, mostly due to the stability Visa displayed. Huang expects Mastercard to see a more muted quarter, with revenue growth decelerating by about 3%. 
That said, this isn&#8217;t necessarily a negative for long-term investors. Mastercard has exposure to significant industry trends, and its market-leading position means it could surprise to the upside, especially if cross-border volumes pick up again. 
Huang sees an &#8220;incrementally positive risk-reward&#8221; scenario, noting that Mastercard's potential for growth remains strong. But with a current price tag of $539.68 and only a 3.31% YTD gain, it's definitely the more volatile pick.
<h2 class="wp-block-heading">Do We Have A Winner In This Payment Face-Off?</h2>
Visa is the safer play for investors looking for stability and reliable returns. The company's diverse portfolio, stable growth, and ability to withstand macro pressures make it a solid choice, especially in uncertain times.
However, if its global volume trends pick up, Mastercard&#8217;s performance could leap significantly for those willing to stomach a little more volatility (and perhaps a potential upside surprise).
In the battle of the payment giants, the question isn&#8217;t whether to bet on one over the other &#8211; it's about how much risk you're willing to take. 
Visa is your steady performer. Mastercard is the one with the higher potential rewards, albeit with a bit more risk. Time to decide where your money goes.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/45075960/mastercard-bets-on-cross-border-payments-with-300-million-corpay-deal">Mastercard Bets On Cross-Border Payments With $300 Million Corpay Deal</a></li>
</ul>
Image: Shutterstock

Analyst Color

Previews

Mastercard Vs. Visa: Two Giants, One Payment War — Who's Ready To Outperform?

ChampionX shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

IPOs

Press Releases

Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering

Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference

Health Care

Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference

Apyx Medical Corporation Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™

Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results

Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 13, 2025

Apyx Medical Corporation Reports Fourth Quarter and Full Year 2024 Financial Results

Renuvion wins 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener"

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

Apyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures

Comments

Apyx Medical

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL